Drug intelligence / Profile preview

KV32a

Development stage: Preclinical
Lead developer: Kensana Health
Modality: Small Molecules
Administration: Topical

Overview

KV32a is a preclinical-stage phytopharmaceutical candidate being developed by Kensana Health for the treatment of autoimmune ulcers. It is designed as a topical wound therapy that modulates the endocannabinoid system (ECS) to promote healing and manage inflammation. While specific molecular targets within the ECS have not been disclosed, the drug is part of Kensana's pipeline focusing on standardized cannabinoid-based treatments for complex wound care and inflammatory conditions. The program is currently in the preclinical phase of development.

Targets

InhA

Beyond the preview

Go deeper on KV32a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KV32a.

Explore the full profile